SCHEMBL15524835

SCHEMBL15524835

O=C(c1c(Cl)ncnc1Cl)c1c(Cl)ncnc1Cl

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.32
DYRK1A Q13627 1/20 0.32
LMNA P02545 1/20 0.32
AXL P30530 1/20 0.32
MKNK1 Q9BUB5 1/20 0.32
MKNK2 Q9HBH9 1/20 0.32
KMO O15229 3/20 0.31
HTT P42858 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPK1 P28482 1/20 0.31
P2RX7 Q99572 1/20 0.31
SLC22A12 Q96S37 1/20 0.31
POLB P06746 1/20 0.30
CHEK1 O14757 1/20 0.30
ADORA3 P0DMS8 1/20 0.30
ADORA2A P29274 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL903214 0.82 ALDH1A1 (0.52) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL2032093 0.81 SMN1; SMN2 (0.43) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL374759 0.81 ALDH1A1 (0.42) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL312212 0.79 L3MBTL1 (0.37) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
Hydrochloric Acid SCHEMBL16053330 0.79 ALDH1A1 (0.41) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL2546883 0.79 POLB (0.45) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
Hydrochloric Acid SCHEMBL17713984 0.79 SMN1; SMN2 (0.42) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL19869979 0.79 LMNA (0.50) SMN1; SMN2LMNAMAPK1L3MBTL1
Formaldehyde SCHEMBL27853879 0.77 SMN1; SMN2 (0.41) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL1349979 0.74 ALDH1A1 (0.50) SMN1; SMN2LMNAHTTALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829010-B2 Pyrazolo[3,4-d]pyrimidine compounds and their use as PDE2 inhibitors and/or CYP3A4 inhibitors PFIZER INC. (US) 2014-09-09 US disclosed
US-20140080806-A1 PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS HELAL CHRISTOPHER JOHN (US) 2014-03-20 US disclosed
CN-103596956-A Pyrazolo[3,4-d]pyrimidine compounds and their use as PDE2 inhibitors and/or cyp3A4 inhibitors PFIZER 2014-02-19 CN disclosed
CN-102869664-A Pyrazolopyrimidine kinase inhibitors VERTEX PHARMA 2013-01-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140080806-A1 PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS PDE12, PDE2A, CYP1A2 PDE4A 9/4885PDE4B 7/4885PDE4C 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.